Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.
Marie Reeberg SassAnne Mette Brandt ChristensenMargit Lykke ChristensenEma GruberHelle NerdrumLone Marianne PedersenMaximilian ReschTroels Højsgaard JørgensenClaus Thorn EkstrømJimmi NielsenTina VilsbøllAnders Fink-JensenPublished in: Acta psychiatrica Scandinavica (2024)
The study did not confirm our hypothesis that liraglutide is a feasible treatment for a minimum of 75% of the patients initiating treatment with liraglutide while hospitalised in a forensic psychiatric department. The high dropout rate may be due to the non-naturalistic setting of the clinical trial. For the proportion of patients compliant with the medication, liraglutide 3.0 mg was an efficient treatment for overweight.
Keyphrases
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- open label
- randomized controlled trial
- emergency department
- healthcare
- radiation therapy
- patient reported outcomes
- weight loss
- study protocol
- patient reported
- phase iii
- replacement therapy
- electronic health record
- placebo controlled